<code id='20785EDE7C'></code><style id='20785EDE7C'></style>
    • <acronym id='20785EDE7C'></acronym>
      <center id='20785EDE7C'><center id='20785EDE7C'><tfoot id='20785EDE7C'></tfoot></center><abbr id='20785EDE7C'><dir id='20785EDE7C'><tfoot id='20785EDE7C'></tfoot><noframes id='20785EDE7C'>

    • <optgroup id='20785EDE7C'><strike id='20785EDE7C'><sup id='20785EDE7C'></sup></strike><code id='20785EDE7C'></code></optgroup>
        1. <b id='20785EDE7C'><label id='20785EDE7C'><select id='20785EDE7C'><dt id='20785EDE7C'><span id='20785EDE7C'></span></dt></select></label></b><u id='20785EDE7C'></u>
          <i id='20785EDE7C'><strike id='20785EDE7C'><tt id='20785EDE7C'><pre id='20785EDE7C'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:37228
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Blinken talks high
          Blinken talks high

          3:35U.S.SecretaryofStateAntonyBlinkenappearson"GoodMorningAmerica,"onJuly11,2023.ABCNewsU.S.Secretar

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          EU fines Illumina $475 million over Grail acquisition

          AdobeLONDON—TheEuropeanUniononWednesdayissuedanantitrustfineof$475milliontotheU.S.geneticsequencingg